FDA delays review of Pfizer's COVID-19 vaccine for young children in surprise shift
Bio Pharma Dive
FEBRUARY 11, 2022
The FDA pushed back plans to expedite review of the shot in children under 5, seeking more data on a third dose. An advisory meeting scheduled for next week has been postponed as a result.
Let's personalize your content